If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...
MarketBeat on MSN
Moderna pops 17% - is there life in MRNA, down 90% from COVID high?
In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results